ERCC2/XPD rs50872 is a C/T polymorphism in intron 4 of XPD. This case-control study linked ERCC2/XPD rs50872 to increased breast cancer risk and showed the polymorphism was more prevalent in the patients with tumor size T3-T4, negative lymph node involvement and patients with ER− and PR− expression, which was consistent with the conclusions in a South Korean population [24]. This evidence concerns the gene PGR and breast carcinoma.